Nalbuphine pretreatment for prevention of etomidate induced myoclonus: A prospective, randomized and double-blind study

Conclusion: Both the groups were comparable with respect to demographic characteristics. Nalbuphine pretreatment significantly reduced the incidence (20% vs. 72%; respiratory rate = 0.294, 95% confidence interval: 0.160–0.496, P < 0.01) and severity of EM without any significant increase in the incidence of adverse effects. Nalbuphine 0.2 mg/kg IV pretreatment significantly reduces the incidence and severity of EM with side-effect profile comparable to saline placebo.

Source: Journal of Anaesthesiology Clinical Pharmacology - July 16, 2018 Category: Anesthesiology Authors: Mayank Gupta Priyanka Gupta Source Type: research